USANA Health Sciences reported a 7% year-over-year increase in net sales, reaching $214 million for Q3 2025. However, the company experienced a net loss of $6.5 million, or -$0.36 diluted EPS, primarily due to softer than anticipated sales, investments in a new Brand Partner compensation plan, and a significant adjustment to the estimated annual effective income tax rate.

USANA Health Sciences delivered positive second quarter results with an 11% year-over-year consolidated net sales growth, reaching $236 million. However, net earnings decreased by 7% to $9.7 million, and diluted EPS fell by 4% to $0.52. The company's direct-to-consumer business, Hiya, continued its strong growth, while the direct selling business is undergoing a comprehensive commercial strategy rollout.

USANA Health Sciences reported net sales of $250 million for Q1 2025, a 10% increase year-over-year, with diluted EPS of $0.49 and adjusted diluted EPS of $0.73. Net earnings were $9.4 million. The company reiterated its full-year 2025 outlook.

USANA Health Sciences reported a decrease in net sales and net earnings for the fourth quarter of 2024 compared to the same period in 2023. Diluted EPS also saw a significant decline. The company completed the acquisition of a controlling stake in Hiya Health Products, which contributed approximately $2 million to net sales in Q4 2024.

USANA Health Sciences reported a decrease in net sales and diluted EPS for the third quarter of 2024 compared to the same period in 2023. Net sales were $200 million, and diluted EPS was $0.56. The company has updated its fiscal year 2024 outlook to approximately $850 million in net sales and $2.45 in diluted EPS.

USANA Health Sciences reported a decrease in net sales and diluted EPS for the second quarter of 2024 compared to the same period in 2023. The company is updating its fiscal year 2024 net sales and diluted EPS outlook due to these challenges.

USANA Health Sciences reported a decrease in net sales and diluted EPS for Q1 2024 compared to Q1 2023. Net sales were $228 million, and diluted EPS was $0.86. The company is reiterating its fiscal year 2024 net sales and diluted EPS outlook.

USANA Health Sciences reported solid fourth-quarter operating results, exceeding expectations with a 3% decrease in net sales to $221 million but a 32% increase in diluted EPS to $0.87. The company's performance was bolstered by a global incentive offering, especially in Greater China, and the commencement of operations in India.

USANA Health Sciences reported a decrease in net sales and diluted EPS for the third quarter of 2023, attributed to challenging economic conditions and reduced promotional activities. The company is narrowing its fiscal year 2023 net sales and diluted EPS outlook.

USANA Health Sciences reported a decrease in net sales to $238 million compared to $264 million in the second quarter of 2022, and diluted EPS was $0.89, down from $1.00 in the same period last year. The company updated its fiscal year 2023 net sales guidance to $900 to $950 million and diluted EPS guidance to $2.65 to $3.30.

USANA Health Sciences reported a decrease in net sales and diluted EPS compared to Q1 2022, but an increase sequentially. Net sales were $248 million and diluted EPS was $0.95. The company has raised the lower end of its net sales and earnings per share guidance for fiscal year 2023.

USANA Health Sciences reported a decrease in net sales to $228 million and diluted EPS to $0.66 for the fourth quarter of 2022, compared to $267 million and $1.03, respectively, in the prior-year period. Active customer counts stabilized in several key markets and increased 3% sequentially. The company is reiterating its fiscal year 2023 net sales and diluted EPS outlook.

USANA Health Sciences reported a decrease in net sales to $233 million compared to $274 million in the prior year quarter. Diluted EPS also decreased to $0.78 versus $1.36 in the third quarter of 2021. The company revised its fiscal year 2022 net sales and diluted EPS outlook to $955 million to $975 million and $3.15 to $3.40, respectively.

USANA Health Sciences reported a decrease in net sales and diluted EPS for the second quarter of 2022, primarily due to COVID-related disruptions in key markets, including mainland China. The company is reiterating its fiscal year 2022 outlook for net sales and diluted EPS.

USANA Health Sciences reported third quarter results modestly ahead of preliminary outlook. Net sales were $274.4 million, a decrease compared to $298.5 million in the prior year. Diluted EPS were $1.36, down from $1.44 in the third quarter of 2020. The company reiterated its fiscal 2021 net sales and diluted EPS outlook and expects to generate approximately $130 million of free cash flow in fiscal 2021.